3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow XC221: new trials by email Literature Review of XC221 trials Research Report on XC221
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections XC221, Placebo - Influenza, Respiratory Viral Infection | Phase 3 | Completed | Valenta Pharm JSC | 260 | 2022-08-05 | 2023-10-10 |
| A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19 XC221, Placebo - Sars-CoV-2 Infection | Phase 3 | Completed | RSV Therapeutics LLC | 274 | 2021-06-26 | 2023-07-27 |
| A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19 XC221, Placebo - SARS-CoV-2 Infection | Phase 3 | Completed | RSV Therapeutics LLC | 118 | 2020-07-25 | 2023-07-27 |
COVID-19 (2) · Coronavirus Infections (2) · Influenza, Human (1)
RSV Therapeutics LLC (2) · Valenta Pharm JSC (1)
Russia (3)